Imbalanced plasma ace and ace2 level in the uremic patients with cardiovascular diseases and its change during a single hemodialysis session
Journal
Renal Failure
Journal Volume
39
Journal Issue
1
Pages
719-728
Date Issued
2017
Author(s)
Abstract
Background: The renin-angiotensin system (RAS) has significant influences on heart and renal disease progression. Angiotensin converting enzyme (ACE) and angiotensin converting enzyme II (ACE2) are major peptidases of RAS components and play counteracting functions through angiotensin II (Ang II)/ATIR and angiotensin-(1–7) (Ang-(1–7))/Mas axis, respectively. Methods: There were 360 uremic patients on regular hemodialysis (HD) treatment (inclusive of 119 HD patients with cardiovascular diseases (CVD) and 241 HD patients without CVD and 50 healthy subjects were enrolled in this study. Plasma ACE, ACE2, Ang II and Ang-(1–7) levels of the HD patients were determined. Results: We compared pre-HD levels of plasma ACE, ACE2, Ang II and Ang-(1–7) in the HD patients with and without CVD to those of the controls. The HD patients, particularly those with CVD, showed a significant increase in the levels of ACE and Ang II, whereas ACE2 and Ang-(1–7) levels were lower than those in the healthy controls. Therefore, imbalanced ACE/ACE2 was observed in the HD patients with CVD. In the course of a single HD session, the plasma ACE, ACE/ACE2 and Ang II levels in the HD patients with CVD were increased from pre-HD to post-HD. On the contrary, ACE2 levels were decreased after the HD session. These changes were not detected in the HD patients without CVD. Conclusions: Pathogenically imbalanced circulating ACE/ACE2 was detected in the HD patients, particularly those with CVD. HD session could increase ACE/Ang II/AT1R axis and decrease ACE2/ Ang-(1–7)/Mas axis activity in the circulation of HD patients with CVD. ? 2017, The Author(s).
Subjects
Angiotensin converting enzyme; Angiotensin converting enzyme II; Cardiovascular diseases; Hemodialysis; Renin-angiotensin system; Uremic patient
SDGs
Other Subjects
angiotensin converting enzyme 2; angiotensin receptor antagonist; angiotensin[1-7]; calcium channel blocking agent; dipeptidyl carboxypeptidase; hydroxymethylglutaryl coenzyme A reductase inhibitor; recombinant erythropoietin; angiotensin converting enzyme 2; dipeptidyl carboxypeptidase; adult; aged; antihypertensive therapy; Article; cardiovascular disease; cerebrovascular accident; chronic kidney failure; congestive heart failure; controlled study; coronary artery disease; female; glomerulus filtration rate; heart infarction; hemodialysis; human; hypertension; major clinical study; male; middle aged; priority journal; prospective study; protein blood level; uremia; blood; cardiovascular disease; complication; uremia; very elderly; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peptidyl-Dipeptidase A; Prospective Studies; Uremia
Publisher
Taylor and Francis Ltd
Type
journal article